The inhaled PDE4 inhibitor tanimilast shows efficacy in both Th2 and non-Th2 murine models of asthma

被引：1
|
作者：
Pisano, Rita [1 ]
Fragni, Debora [1 ]
Allen, Andrew [1 ]
Tondelli, Marina [1 ]
Pappani, Alice [1 ]
De Angelis, Davide [1 ]
Civelli, Maurizio [1 ]
Villetti, Gino [1 ]
Miglietta, Daniela [1 ]
机构：
[1] Chiesi Farmaceutici SpA, Parma, PR, Italy
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
Asthma. Pharmacology. Animal models;
D O I：
10.1183/13993003.congress-2023.OA4305
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis
    Ratziu, Vlad
    Bedossa, Pierre
    Francque, Sven M.
    Larrey, Dominique
    Aithal, Guruprasad P.
    Serfaty, Lawrence
    Voiculescu, Mihai
    Preotescu, Liliana
    Nevens, Frederik
    De Ledinghen, Victor
    Kirchner, Gabriele I.
    Trunecka, Pavel
    Ryder, Stephen D.
    Day, Christopher P.
    Takeda, Jun
    Traudtner, Klaudia
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (10) : 1724 - U202
  • [22] Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma
    Takanobu Shioya
    Masahiro Satake
    Masaaki Sano
    Manabu Kagaya
    Akiko Watanabe
    Kazuhiro Sato
    Takeshi Ito
    Nobuaki Ito
    Masahiro Sasaki
    Mamoru Miura
    European Journal of Clinical Pharmacology, 2002, 58 : 171 - 176
  • [23] Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma
    Shioya, T
    Satake, M
    Sano, M
    Kagaya, M
    Watanabe, A
    Sato, K
    Ito, T
    Ito, N
    Sasaki, M
    Miura, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (03) : 171 - 176
  • [24] TH1/TH2 cytokine balance in patients with both type 1 diabetes mellitus and asthma
    Rachmiel, Marianna
    Bloch, Olga
    Bistritzer, Tzvi
    Weintrob, Naomi
    Ofan, Regina
    Koren-Morag, Nira
    Rapoport, Micha J.
    CYTOKINE, 2006, 34 (3-4) : 170 - 176
  • [25] CTLA-4 polymorphisms in allergy and asthma and the TH1/TH2 paradigm
    Munthe-Kaas, MC
    Carlsen, KH
    Helms, PJ
    Gerritsen, J
    Whyte, M
    Feijen, M
    Skinningsrud, B
    Main, M
    Kwong, GNM
    Lie, BA
    Carlsen, KCL
    Undlien, DE
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (02) : 280 - 287
  • [26] Disturbance in bacterial community composition affects inflammatory ambiance and structural changes in non-Th2 asthma
    Konishcheva, Anna
    Gervazieva, Valentina
    Ospelnikova, Tatyana
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [27] Chronic aspiration shifts the immune response from Th1 to Th2 in a murine model of asthma
    Barbas, A. S.
    Downing, T. E.
    Balsara, K. R.
    Tan, H. E.
    Rubinstein, G. J.
    Holzknecht, Z. E.
    Collins, B. H.
    Parker, W.
    Davis, R. D.
    Lin, S. S.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 (08) : 596 - 602
  • [28] Rapamycin-generated Th2 cell therapy of established acute murine GVHD requires Th2 cell secretion of both IL-4 and IL-10
    Foley, J. E.
    Mariotti, J.
    Borenstein, T.
    Han, S.
    Eckhaus, M.
    Fowler, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 105 - 105
  • [29] Transient corticosteroid treatment permanently amplifies the Th2 response in a murine model of asthma
    Wiley, RE
    Cwiartka, M
    Alvarez, D
    Mackenzie, DC
    Johnson, JR
    Goncharova, S
    Lundblad, L
    Jordana, M
    JOURNAL OF IMMUNOLOGY, 2004, 172 (08): : 4995 - 5005
  • [30] Atractylenolide III reduces NLRP3 inflammasome activation and Th1/Th2 imbalances in both in vitro and in vivo models of asthma
    Zhu, Cuimin
    Zhang, Leguo
    Liu, Zhiming
    Li, Chen
    Bai, Yajie
    Wang, Linlin
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2020, 47 (08) : 1360 - 1367
12345